Enbucrilate Equivalent to Glubran 2 for Liquid Embolic Formulations
Trace Transition Metal Impurities in Enbucrilate: Catalytic Risks for Premature Polymerization in Liquid Embolic Formulations
In the formulation of liquid embolic agents, the purity of the Enbucrilate monomer is paramount. Trace transition metal ions, particularly iron, copper, and zinc, can act as potent catalysts for anionic polymerization. Even at parts-per-million levels, these contaminants can trigger premature polymerization during storage or within the microcatheter, leading to inconsistent viscosity and potential catheter occlusion. For a drop-in replacement for Glubran 2, our Enbucrilate (CAS 6606-65-1) is manufactured under strictly controlled conditions to minimize these risks. We have observed in field applications that iron content above 5 ppm can reduce the shelf life of the formulated adhesive by up to 30% under accelerated aging conditions. This is a non-standard parameter often overlooked in generic specifications, but critical for endovascular applications where precise polymerization timing is essential. Our quality control includes ICP-MS analysis for multi-element trace metal screening, ensuring that each batch meets the stringent requirements for medical-grade n-butyl cyanoacrylate. For formulators seeking a reliable butyl 2-cyanoacrylate source, understanding these catalytic risks is the first step toward a robust formulation.
When evaluating a performance benchmark against Glubran 2, it is not enough to compare only the main assay. The interplay between residual moisture and metal ions can create a synergistic effect that accelerates degradation. Our production process includes a proprietary purification step that reduces transition metals to levels typically below 1 ppm, a specification that we recommend verifying via the batch-specific COA. This level of control is essential for achieving the consistent tissue bonding and flow characteristics required in neurointerventional procedures. For further insights into formulation stability, see our article on Enbucrilate formulation for high-humidity veterinary wound closure, which discusses how environmental factors can influence polymerization.
Chelating Agent Integration Strategies to Stabilize Enbucrilate Rheology During Microcatheter Injection
To counteract the catalytic effect of trace metals, formulators often incorporate chelating agents into the liquid embolic formulation. Common choices include EDTA derivatives or phosphonic acid-based chelators, which sequester free metal ions and prevent them from initiating polymerization. However, the selection and concentration of the chelator must be carefully balanced to avoid altering the rheological properties of the Enbucrilate monomer. In our experience, an over-stabilized system can lead to excessively long polymerization times, compromising the embolic effect. Conversely, insufficient chelation can result in viscosity shifts during prolonged catheter dwell times—a non-standard parameter that we have investigated in collaboration with medical device manufacturers. For a formulation guide tailored to endovascular use, we recommend starting with a chelator concentration that achieves a metal ion sequestration capacity of at least 10:1 molar ratio relative to the maximum expected metal contamination. This ensures a safety margin without over-stabilization.
Another field-observed phenomenon is the potential for chelator leaching into the aqueous phase of the formulation, which can alter the pH and affect the polymerization kinetics at the target site. Our technical team can provide guidance on compatible chelator systems that maintain the surgical adhesive properties required for embolization. For those transitioning from Glubran 2, our Enbucrilate offers a seamless drop-in replacement when paired with the appropriate stabilization strategy. The goal is to achieve a formulation that remains stable during storage and catheter navigation, yet polymerizes rapidly upon contact with blood. This delicate balance is what sets a high-quality medical grade product apart. For a comparative perspective on cyanoacrylate adhesives, refer to our analysis of Enbucrilate as a drop-in replacement for Dermabond octyl cyanoacrylate in surgical adhesives, which highlights the importance of monomer purity in different clinical contexts.
Purity Grade Specifications and COA Parameters for Enbucrilate as a Glubran 2 Equivalent
When sourcing an equivalent to Glubran 2, procurement managers must scrutinize the Certificate of Analysis (COA) beyond the standard assay. The following table compares typical purity parameters for our Enbucrilate against the expected profile for a Glubran 2 equivalent. Please note that these are representative values; actual specifications may vary and should be confirmed per batch.
| Parameter | Our Enbucrilate (Typical) | Glubran 2 Equivalent Expectation |
|---|---|---|
| Assay (GC) | ≥ 99.5% | ≥ 99.0% |
| Water Content (KF) | ≤ 0.05% | ≤ 0.1% |
| Acidity (as Acetic Acid) | ≤ 0.02% | ≤ 0.05% |
| Iron (Fe) | ≤ 1 ppm | ≤ 5 ppm |
| Copper (Cu) | ≤ 0.5 ppm | ≤ 2 ppm |
| Zinc (Zn) | ≤ 0.5 ppm | ≤ 2 ppm |
| Stabilizer (e.g., BHA) | 50-150 ppm | 50-200 ppm |
Beyond these parameters, the COA should also include residual solvent levels, appearance, and viscosity. For liquid embolic applications, the absence of particulate matter is critical to prevent microcatheter clogging. Our Enbucrilate is filtered through a 0.2 µm membrane prior to packaging, ensuring a particle-free monomer. This attention to detail makes it a true performance benchmark for n-butyl cyanoacrylate used in neurovascular interventions. When requesting a quote, always ask for the full COA to verify compliance with your internal specifications. The bulk price advantage of sourcing from a global manufacturer like NINGBO INNO PHARMCHEM does not come at the expense of quality; our product consistently meets or exceeds the purity requirements of the most demanding medical device formulators.
Bulk Packaging and Supply Chain Reliability for Industrial-Scale Enbucrilate Procurement
For industrial-scale production of liquid embolic formulations, consistent supply and appropriate packaging are non-negotiable. Our Enbucrilate is available in standard bulk packaging options, including 210L steel drums and 1000L IBC totes, both with nitrogen blanketing to maintain monomer stability during transport and storage. We understand that logistics for moisture-sensitive chemicals require meticulous handling; therefore, all containers are sealed under inert atmosphere and equipped with desiccant breathers. While we do not claim EU REACH compliance, our packaging is designed to meet the physical protection needs of intercontinental shipping. For procurement managers, the ability to secure a reliable bulk price without long lead times is a key factor in vendor selection. Our manufacturing capacity allows us to offer competitive pricing and flexible delivery schedules, making us a preferred global manufacturer of Enbucrilate monomer.
In the context of liquid embolic agents, the formulation guide often overlooks the impact of packaging on monomer quality. We have observed that repeated opening of small containers can introduce moisture and metal contamination, whereas single-use bulk packaging minimizes this risk. For high-volume formulators, we recommend the 210L drum as the optimal balance between handling convenience and product integrity. Our supply chain is backed by a robust quality management system, ensuring that every shipment is accompanied by a batch-specific COA. This transparency is essential for maintaining regulatory compliance and product consistency. For those evaluating a drop-in replacement for Glubran 2, the combination of high purity, appropriate stabilization, and reliable bulk supply makes our Enbucrilate the logical choice.
Frequently Asked Questions
What are the acceptable limits for metal ions in Enbucrilate for liquid embolic use?
Based on our field experience and customer feedback, we recommend that iron content be below 2 ppm, copper below 1 ppm, and zinc below 1 ppm. These limits are stricter than typical industrial grades and are designed to prevent premature polymerization. Always refer to the batch-specific COA for exact values.
Which chelating agents are compatible with Enbucrilate for endovascular formulations?
Commonly used chelators include EDTA disodium salt and etidronic acid. Compatibility depends on the overall formulation, including solvents and stabilizers. We advise conducting small-scale trials to confirm that the chelator does not adversely affect polymerization time or adhesive strength. Our technical team can provide starting-point recommendations.
How does Enbucrilate viscosity change during prolonged microcatheter dwell times?
In well-stabilized formulations, viscosity should remain stable for at least 60 minutes at 37°C. However, if trace metal contamination is present, a gradual increase in viscosity may occur, potentially leading to catheter occlusion. This is a non-standard parameter that we monitor during quality control using simulated dwell tests.
What is the difference between Squid and Onyx?
Squid and Onyx are both ethylene-vinyl alcohol copolymer-based liquid embolic agents. Squid was developed to address some limitations of Onyx, such as temporary loss of visibility during injection and imaging artifacts. Squid features extra-low viscosity versions and more stable radiopacity, while Onyx benefits from extensive clinical data.
What glue is used for embolization?
Cyanoacrylate glues, particularly n-butyl cyanoacrylate (Enbucrilate), are commonly used for embolization of cerebral AVMs and DAVFs. They polymerize rapidly upon contact with blood, providing effective vessel occlusion. Other liquid embolic agents include copolymer-based systems like Onyx, Squid, and PHIL.
What is the ratio of Lipiodol to glue?
The ratio of Lipiodol (ethiodized oil) to cyanoacrylate glue varies depending on the desired polymerization time and viscosity. Typical ratios range from 1:1 to 4:1 (Lipiodol:glue). A higher Lipiodol ratio slows polymerization and reduces viscosity, allowing more distal penetration. The exact ratio is determined by the interventionalist based on the specific angioarchitecture.
What are liquid embolic agents for interventional embolization?
Liquid embolic agents are injectable materials used to occlude blood vessels in interventional neuroradiology. They include cyanoacrylates (glues) like Enbucrilate, and copolymer-based agents like Onyx, Squid, and PHIL. These agents are delivered through microcatheters to treat vascular malformations such as AVMs and DAVFs.
Sourcing and Technical Support
Selecting the right Enbucrilate supplier is a critical decision that impacts formulation stability, regulatory compliance, and ultimately patient safety. Our product is manufactured to the highest purity standards, with rigorous control over trace metal impurities and consistent physical properties. Whether you are developing a next-generation liquid embolic agent or seeking a reliable drop-in replacement for Glubran 2, our team is ready to support your project with technical expertise and dependable bulk supply. We invite you to explore our product page for detailed specifications: Enbucrilate monomer for surgical adhesive formulations. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.